Muscle Atrophy In Patients With Chronic Obstructive Pulmonary Disease

NCT02284932 | Unknown DMC

• 1 other identifier: COPD-20739
• Study Type: observational
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

Limb muscle dysfunction, characterized by atrophy and weakness, is amongst the most troublesome systemic consequences of chronic obstructive pulmonary disease (COPD) leading to poor functional status and premature mortality. One prevailing hypothesis stipulates that the deterioration in muscle structure and function during COPD results from a spillover of inflammatory mediators from the lungs to the systemic circulation and then to the muscles.

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

COPD; atrophy; muscle

Outcome Measures

Primary Outcomes (1)

• Decrease of protein degradation in muscles of wasted COPD patients

  At baseline (COPD in a stable state of the disease)

Secondary Outcomes (1)

• Increase of protein synthesis in muscles of wasted COPD patients

  At baseline (COPD in a stable state of the disease)

Study Arms (2)

COPD patients

Group : COPD patients No specific intervention for this study

Other: No specific intervention for this study

Healthy controls

Group : healthy volunteers No specific intervention for this study

Other: No specific intervention for this study

Interventions

No specific intervention for this study OTHER

No specific intervention for this study

COPD patients; Healthy controls

Eligibility Criteria

• Age: 55 Years - 75 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with COPD

You may qualify if:

• male
• COPD with an FEV1 of under 60% of predicted
• non-smoker
• between 55 and 75 years old

You may not qualify if:

• all inflammatory disease (HIV, cancer, renal and cardiac deficiency)
• hormonal dysregulation
• inferior limb pathology
• neuromuscular pathology
• history of tobacco or alcool abuse
• oxygen dependent
• recent exacerbation (2 months) of the symptoms of COPD

Sponsors & Collaborators

• Laval University: lead
• Canadian Institutes of Health Research (CIHR): collaborator

Study Sites (1)

Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec

Québec, Quebec, G1V 4G5, Canada

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood sample and muscle biopsy of vastus lateralis (quadriceps)

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive; Atrophy

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Pathological Conditions, Anatomical

Study Officials

• François Maltais, MD, PhD

  Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 6 Weeks
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professionelle de recherche

Study Record Dates

• First Submitted: October 8, 2014
• First Posted: November 6, 2014
• Study Start: September 1, 2011
• Primary Completion: September 1, 2017
• Study Completion: September 1, 2018
• Last Updated: September 8, 2016

Record last verified: 2016-09

Locations

CA (1)